Canopy Growth (CGC)
(Delayed Data from NSDQ)
$6.21 USD
+0.07 (1.14%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Canopy Growth Corporation (CGC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$5.71 | $13.10 | $2.00 | -7.00% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Canopy Growth Corporation comes to $5.71. The forecasts range from a low of $2.00 to a high of $13.10. The average price target represents a decline of 7% from the last closing price of $6.14.
Analyst Price Targets (10)
Broker Rating
Canopy Growth Corporation currently has an average brokerage recommendation (ABR) of 3.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 3.64 a month ago based on 11 recommendations.
Of the 10 recommendations deriving the current ABR, one is Strong Buy, representing 10% of all recommendations. A month ago, Strong Buy represented 9.09%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CGC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 3 | 4 | 4 | 4 | 4 |
ABR | 3.50 | 3.64 | 3.64 | 3.64 | 3.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | Canaccord Genuity | Matt Bottomley | Strong Sell | Strong Sell |
7/9/2024 | Piper Sandler | Michael S Lavery | Strong Sell | Strong Sell |
6/18/2024 | ATB Capital Markets | Frederico Gomes | Hold | Hold |
6/11/2024 | Not Identified | Not Identified | Hold | Hold |
6/4/2024 | Alliance Global Partners | Aaron Grey | Hold | Hold |
5/31/2024 | CIBC World Markets Corp. | John Zamparo | Strong Sell | Strong Sell |
5/31/2024 | Roth Capital Partners | William Kirk | Strong Buy | Strong Buy |
2/12/2024 | BMO Capital Markets | Tamy Chen | Hold | Hold |
1/31/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.50 |
ABR (Last week) | 3.64 |
# of Recs in ABR | 10 |
Average Target Price | $5.71 |
LT Growth Rate | 49.80% |
Industry | Medical - Products |
Industry Rank by ABR | 99 of 253 |
Current Quarter EPS Est: | -0.34 |